drugset / Trial / NCT05934331
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.
Timeline
- Start
- 2023-07-27
- Primary completion
- 2026-07-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Rivoceranib | Small molecule | — | Oral |
| Subject | TPX4589 | Unknown | — | Intravenous |
| Subject | Tegafur, Gimeracil and Oteracil Potassium Capsules | Unknown | — | Oral |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |